Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ.
Versluis J, et al. Among authors: lowenberg b.
Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.
Leukemia. 2017.
PMID: 27416910
Free article.